SCHEMBL490929

SCHEMBL490929

N[C@@H]1CCCC[C@H]1N(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC18A3 Q16572 3/20 0.49
G6PC1 P35575 1/20 0.41
OPRM1 P35372 3/20 0.40
CA2 P00918 1/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
OPRK1 P41145 2/20 0.38
OPRD1 P41143 1/20 0.38
AOC3 Q16853 1/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
ALDH1A1 P00352 3/20 0.38
SIGMAR1 Q99720 1/20 0.37
TSHR P16473 1/20 0.36
KDM4E B2RXH2 1/20 0.36
GAA P10253 1/20 0.36
ALOX12 P18054 1/20 0.36
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
YTHDC1 Q96MU7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29615873 1.00 SLC18A3 (0.49) SLC18A3G6PC1OPRM1CA2SLC6A2
SCHEMBL2197649 1.00 SLC18A3 (0.49) SLC18A3G6PC1OPRM1CA2SLC6A2
SCHEMBL2936927 1.00 SLC18A3 (0.49) SLC18A3G6PC1OPRM1CA2SLC6A2
Bromide SCHEMBL19897108 0.98 SLC18A3 (0.47) SLC18A3G6PC1OPRM1CA2SLC6A2
Bromide SCHEMBL19897327 0.98 SLC18A3 (0.47) SLC18A3G6PC1OPRM1CA2SLC6A2
Bromide SCHEMBL16799712 0.98 SLC18A3 (0.47) SLC18A3G6PC1OPRM1CA2SLC6A2
Bromide SCHEMBL20398790 0.97 SLC18A3 (0.46) SLC18A3G6PC1OPRM1CA2SLC6A2
SCHEMBL25209581 0.83 SLC18A3 (0.48) SLC18A3G6PC1OPRM1CA2SLC6A2
SCHEMBL28811067 0.83 SLC18A3 (0.44) SLC18A3OPRM1SLC6A2SLC6A4OPRK1
SCHEMBL6431460 0.83 SIGMAR1 (0.37) SLC18A3SLC6A2SLC6A4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050288525-A1 Reagents for asymmetric allylation, aldol, and tandem aldol and allylation reactions NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-12-29 US claimed
EP-2408752-B1 SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF CANCER BOEHRINGER INGELHEIM INT (DE) 2015-08-12 EP disclosed
US-20140051674-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-20 US disclosed
US-8540966-B2 Contrast agents endowed with high relaxivity BRACCO IMAGING S.P.A. (IT) 2013-09-24 US disclosed
US-8105567-B2 Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy BRACCO IMAGING SPA (IT) 2012-01-31 US disclosed
US-20110256067-A1 Contrast agents endowed with high relaxivity BRACCO IMAGING SPA (IT) 2011-10-20 US disclosed
US-7988950-B2 Contrast agents endowed with high relaxivity for use in magnetic resonance imaging (MRI) which contain a chelating moiety with polyhydroxylated substituents BRACCO IMAGING S.P.A. (IT) 2011-08-02 US disclosed
US-20110082280-A1 Methods Of Coupling Multidentate AZA Ligands To Targeting Molecules BRACCO IMAGING S.P.A. (IT) 2011-04-07 US disclosed
US-20110071158-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-03-24 US disclosed
US-7893223-B2 Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy BRACCO IMAGING S.P.A. (IT) 2011-02-22 US disclosed
EP-2114899-B1 CONTROLLED RELEASE OF ACTIVE ALDEHYDES AND KETONES FROM EQUILIBRATED DYNAMIC MIXTURES FIRMENICH & CIE (CH) 2010-09-22 EP disclosed
US-20100160681-A1 Chiral phosphoramides, chiral N-phosphonimines and methods for forming the same NOWA PHARMACEUTICALS, CO., LTD. (CN) 2010-06-24 US disclosed
US-20100098650-A1 CONTROLLED RELEASE OF ACTIVE ALDEHYDES AND KETONES FROM EQUILIBRATED DYNAMIC MIXTURES FIRMENICH SA (CH) 2010-04-22 US disclosed
US-20100069628-A1 Multidentate AZA Ligands Able to Complex Metal Ions And The Use Thereof In Diagnostics And Therapy BRACCO IMAGING S.P.A (IT) 2010-03-18 US disclosed
US-7534905-B2 Reagents for asymmetric allylation, aldol, and tandem aldol and allyation reactions THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2009-05-19 US disclosed
EP-1765812-B1 CONTRAST AGENTS ENDOWED WITH HIGH RELAXIVITY FOR USE IN MAGNETIC RESONANCE IMAGING (MRI) WHICH CONTAIN A CHELATING MOIETY WITH POLYHYDROXYLATED SUBSTITUENTS BRACCO IMAGING SPA (IT) 2009-04-29 EP disclosed
EP-1786475-B1 1,4-BIS(CARBOXYMETHYL)-6-[BIS(CARBOXYMETHYL)AMINO]-6-METHYL-PERHYDRO-1,4-DIAZEPINE (AAZTA) DERIVATIVES AS LIGANDS IN HIGH RELAXIVITY CONTRAST AGENTS FOR USE IN MAGNETIC RESONANCE IMAGING (MRI) BRACCO IMAGING SPA (IT) 2009-04-29 EP disclosed
US-20070258905-A1 Contrast Agents Endowed with High Relaxivity for Use in Magnetic Resonance Imaging (Mri) Which Contain a Chelating Moiety with Polyhydroxylated Substituents BRACCO IMAGING SPA (IT) 2007-11-08 US disclosed
US-20060034773-A1 Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy BRACCO IMAGING SPA (IT) 2006-02-16 US disclosed
US-20050288525-A1 Reagents for asymmetric allylation, aldol, and tandem aldol and allylation reactions NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060034773-A1 Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy SSTR3, MB, CA13 SLC18A3 2202/4885G6PC1 1609/4885OPRM1 105/4885
US-20110256067-A1 Contrast agents endowed with high relaxivity SLC40A1, SLC67A1, SLC19A1 SLC18A3 199/4885G6PC1 4139/4885OPRM1 949/4885
US-20110082280-A1 Methods Of Coupling Multidentate AZA Ligands To Targeting Molecules CD99, CD209, PRMT9 SLC18A3 1894/4885G6PC1 2007/4885OPRM1 204/4885
US-20140051674-A1 NEW COMPOUNDS CCNA1, MKI67, CCNT1 SLC18A3 3182/4885G6PC1 413/4885OPRM1 342/4885
US-20110071158-A1 NEW COMPOUNDS CCNA1, MKI67, CCNT1 SLC18A3 3182/4885G6PC1 413/4885OPRM1 342/4885
US-20100160681-A1 Chiral phosphoramides, chiral N-phosphonimines and methods for forming the same PHOSPHO1, PNP, CDK2 SLC18A3 4338/4885G6PC1 1299/4885OPRM1 892/4885
US-20100098650-A1 CONTROLLED RELEASE OF ACTIVE ALDEHYDES AND KETONES FROM EQUILIBRATED DYNAMIC MIXTURES PKM, APEH, PLG SLC18A3 609/4885G6PC1 3965/4885OPRM1 623/4885
US-20050288525-A1 Reagents for asymmetric allylation, aldol, and tandem aldol and allylation reactions AKR1C3, AKR1B10, CBR3 SLC18A3 3903/4885G6PC1 3643/4885OPRM1 245/4885
US-20070258905-A1 Contrast Agents Endowed with High Relaxivity for Use in Magnetic Resonance Imaging (Mri) Which Contain a Chelating Moiety with Polyhydroxylated Substituents RXFP1, SLC5A7, SLC40A1 SLC18A3 127/4885G6PC1 4304/4885OPRM1 890/4885
US-20100069628-A1 Multidentate AZA Ligands Able to Complex Metal Ions And The Use Thereof In Diagnostics And Therapy CD99, MB, HBZ SLC18A3 2262/4885G6PC1 2318/4885OPRM1 398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.